Manuel Castro-Fernández

Manuel Castro-Fernández

Auto-generated profile, based on publicly available information

Manuel Castro-Fernández

Department of Gastroenterology, Hospital Universitario de Valme, Seville, Spain

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
JMJavier Molina-Infante
Javier Molina-Infante
JAJavier Amador
Javier Amador
FBFernando Bermejo
Fernando Bermejo
LBLuis Bujanda
Luis Bujanda
AMAdrián G. McNicholl
Adrián G. McNicholl

23 February 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JGJavier P Gisbert
Javier P Gisbert
MRM. Romano
M. Romano
AGAntonietta Gerarda Gravina
Antonietta Gerarda Gravina
PSP. Solís‐Muñoz
P. Solís‐Muñoz
FBF. Bermejo
F. Bermejo
AMAdrian Gerald McNicholl
Adrian Gerald McNicholl
Summary: Background: The most commonly used second‐line Helicobacter pylori eradication regimens are bismuth‐containing quadruple therapy and levofloxacin‐containing triple therapy, both offering suboptimal results. Combining bismuth and levofloxacin may enhance the efficacy of rescue eradication regimens.Aims: To evaluate the efficacy and tolerability of a second‐line quadruple regimen containing levofloxacin and bismuth in patients whose previous H. pylori eradication treatment failed.Methods: This was a prospective multicenter study including patients in whom a standard triple therapy (PPI–clarithromycin–amoxicillin) or a non‐bismuth quadruple therapy (PPI–clarithromycin–amoxicillin–metronidazole, either sequential or concomitant) had failed. Esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), levofloxacin (500 mg o.d.) and bismuth (240 mg b.d.) was prescribed for 14 days. Eradication was confirmed by 13C‐urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by questionnaires.Results: 200 patients were included consecutively (mean age 47 years, 67% women, 13% ulcer). Previous failed therapy included: standard clarithromycin triple therapy (131 patients), sequential (32) and concomitant (37). A total of 96% took all medications correctly. Per‐protocol and intention‐to‐treat eradication rates were 91.1% (95%CI = 87–95%) and 90% (95%CI = 86–94%). Cure rates were similar regardless of previous (failed) treatment or country of origin. Adverse effects were reported in 46% of patients, most commonly nausea (17%) and diarrhoea (16%); 3% were intense but none was serious.Conclusions: Fourteen‐day bismuth‐ and levofloxacin‐containing quadruple therapy is an effective (≥90% cure rate), simple and safe second‐line strategy in patients whose previous standard triple or non‐bismuth quadruple (sequential or concomitant) therapies have failed.

1 February 2006 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
MCManuel Castro-Fernandez
Manuel Castro-Fernandez
FBFernando Bermejo
Fernando Bermejo
APAngeles Perez-Aisa
Angeles Perez-Aisa
JDJulio Ducons
Julio Ducons
TGThe H. pylori Study Group of the Asociacion Espanola de Gastroenterologia
The H. pylori Study Group of the Asociacion Espanola de Gastroenterologia
Eradication therapy with proton pump inhibitor, clarithromycin and amoxicillin fails in a considerable number of cases. A rescue therapy still fails in more than 20% of the cases. Our aim was to evaluate the efficacy and tolerability of a third-line levofloxacin-based regimen in patients with two consecutive Helicobacter pylori eradication failures. Prospective multicenter study. In whom a first treatment with omeprazole-clarithromycin-amoxicillin and a second with omeprazole-bismuth-tetracycline-metronidazole (or ranitidine bismuth citrate with these antibiotics) had failed. A third eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.) was prescribed for 10 days. Eradication was confirmed with 13C-urea breath test 4-8 wk after therapy. One-hundred patients were initially included, and nine were lost for follow-up. All patients but five took all the medications correctly. Per-protocol and intention-to-treat eradication rates were 66% (95% CI = 56-75%) and 60% (50-70%). Adverse effects were reported in 25% of the patients, mainly including metallic taste (8%), nausea (8%), myalgia/arthralgia (5%), and diarrhea (4%); none of them were severe. Levofloxacin-based rescue therapy constitutes an encouraging empirical third-line strategy after multiple previous H. pylori eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, and tetracycline.

1 May 2013 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
XCXavier Calvet
Xavier Calvet
FBFernando Bermejo
Fernando Bermejo
DBDaniel Boixeda
Daniel Boixeda
FBFelipe Bory
Felipe Bory
JSJordi Sánchez-Delgado
Jordi Sánchez-Delgado

1 January 2008 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
JGJavier P Gisbert
Javier P Gisbert
FBFernando Bermejo
Fernando Bermejo
MCManuel Castro-Fernández
Manuel Castro-Fernández
APAngeles Pérez-Aisa
Angeles Pérez-Aisa
MFMiguel Fernández-Bermejo
Miguel Fernández-Bermejo
XCXavier Calvet
Xavier Calvet
Quadruple therapy is generally recommended as second-line therapy after Helicobacter pylori (H. pylori) eradication failure. However, this regimen requires the administration of four drugs with a complex scheme, is associated with a relatively high incidence of adverse effects, and bismuth salts are not available worldwide anymore. Our aim was to evaluate the efficacy and tolerability of a triple second-line levofloxacin-based regimen in patients with H. pylori eradication failure. Design: Prospective multicenter study. Patients: in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin had failed. Intervention: A second eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.) was prescribed for 10 days. Outcome: Eradication was confirmed with 13C-urea breath test 4–8 wk after therapy. Compliance with therapy was determined from the interview and the recovery of empty envelopes of medications. Incidence of adverse effects was evaluated by means of a specific questionnaire. Three hundred consecutive patients were included. Mean age was 48 yr, 47% were male, 38% had peptic ulcer, and 62% functional dyspepsia. Almost all (97%) patients took all the medications correctly. Per-protocol and intention-to-treat eradication rates were 81% (95% CI 77–86%) and 77% (73–82%). Adverse effects were reported in 22% of the patients, mainly including nausea (8%), metallic taste (5%), abdominal pain (3%), and myalgias (3%); none of them were severe. Ten-day levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous proton pump inhibitor-clarithromycin-amoxicillin failure, being simple and safe.

1 February 2013 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
ÁPÁngeles Pérez-Aisa
Ángeles Pérez-Aisa
FBFernando Bermejo
Fernando Bermejo
MCManuel Castro-Fernández
Manuel Castro-Fernández
PAPedro Almela
Pedro Almela
XCXavier Calvet
Xavier Calvet
Second-line bismuth-containing quadruple therapy is complex and frequently induces adverse effects. A triple rescue regimen containing levofloxacin is a potential alternative; however, resistance to quinolones is rapidly increasing. To evaluate the efficacy and tolerability of a second-line triple-regimen-containing levofloxacin in patients whose Helicobacter pylori eradication treatment failed and to assess whether the efficacy of the regimen decreases with time. Prospective multicenter study. In whom treatment with a regimen comprising a proton-pump inhibitor, clarithromycin, and amoxicillin had failed. Levofloxacin (500 mg bid), amoxicillin (1 g bid), and omeprazole (20 mg bid) for 10 days. Eradication was confirmed using the C-urea breath test 4 to 8 weeks after therapy. Compliance/tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. The study sample comprised 1000 consecutive patients (mean age, 49 ± 15 y, 42% men, 33% peptic ulcer) of whom 97% took all medications correctly. Per-protocol and intention-to-treat eradication rates were 75.1% (95% confidence interval, 72%-78%) and 73.8% (95% confidence interval, 71%-77%). Efficacy (intention-to-treat) was 76% in the year 2006, 68% in 2007, 70% in 2008, 76% in 2009, 74% in 2010, and 81% in 2011. In the multivariate analysis, none of the studied variables (including diagnosis and year of treatment) were associated with success of eradication. Adverse effects were reported in 20% of patients, most commonly nausea (7.9%), metallic taste (3.9%), myalgia (3.1%), and abdominal pain (2.9%). Ten-day levofloxacin-containing therapy is an encouraging second-line strategy, providing a safe and simple alternative to quadruple therapy in patients whose previous standard triple therapy has failed. The efficacy of this regimen remains stable with time.